Note 15 - Subsequent Event and Other Information

3 Months Ended

Mar. 31, 2020

Notes to Financial Statements

Subsequent Events [Text Block]

 

15.

Asset

s

Held for Sale

During the

three

months ended

March 31, 2020,

in connection with our planned transfer of the manufacturing of our Omniflow II ovine biologic graft to our Burlington, Massachusetts facility, management committed to and executed a plan to sell our land and building located in North Melbourne, Australia for

A$2.7

million (

$1.7

million). The sale is expected to close in

September 2020,

though

no

assurance can be given that the sale will be consummated at such time, or at all. These assets, with a net book value of

A$1.9

million (

$1.2

million) as of

March 31, 2020,

met the criteria to be classified as assets held for sale as of that date.